LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Search

Ligand Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

181.99 -0.62

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

179.25

Max

185.95

Pagrindiniai rodikliai

By Trading Economics

Pajamos

112M

117M

Pardavimai

115M

P/E

Sektoriaus vid.

81.352

77.671

Pelno marža

101.569

Darbuotojai

68

EBITDA

87M

149M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+31.03% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-485M

3.6B

Ankstesnė atidarymo kaina

182.61

Ankstesnė uždarymo kaina

181.99

Naujienos nuotaikos

By Acuity

56%

44%

329 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-10 22:02; UTC

Uždarbis

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

2025-12-10 21:46; UTC

Uždarbis

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

2025-12-10 23:52; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

2025-12-10 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise After Fed Rate Cut -- Market Talk

2025-12-10 23:36; UTC

Rinkos pokalbiai

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

2025-12-10 23:20; UTC

Uždarbis

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

2025-12-10 23:15; UTC

Uždarbis

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

2025-12-10 22:59; UTC

Rinkos pokalbiai
Uždarbis
Įsigijimai, susijungimai, perėmimai

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

2025-12-10 22:45; UTC

Rinkos pokalbiai

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

2025-12-10 22:40; UTC

Uždarbis

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

2025-12-10 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

2025-12-10 22:06; UTC

Uždarbis

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

2025-12-10 22:02; UTC

Uždarbis

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

2025-12-10 22:00; UTC

Uždarbis

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

2025-12-10 21:53; UTC

Uždarbis

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

2025-12-10 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Investors Bet That a Higher Bid for Warner Is Coming -- Update

2025-12-10 21:50; UTC

Rinkos pokalbiai
Uždarbis
Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2025-12-10 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-12-10 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-12-10 21:45; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

2025-12-10 21:33; UTC

Uždarbis

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

2025-12-10 21:32; UTC

Uždarbis

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

2025-12-10 21:28; UTC

Įsigijimai, susijungimai, perėmimai

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

2025-12-10 21:25; UTC

Uždarbis

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

2025-12-10 21:18; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

2025-12-10 21:16; UTC

Uždarbis

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

2025-12-10 21:15; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

2025-12-10 21:15; UTC

Uždarbis

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

2025-12-10 21:14; UTC

Uždarbis

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

2025-12-10 21:14; UTC

Uždarbis

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Akcijų palyginimas

Kainos pokytis

Ligand Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

31.03% į viršų

12 mėnesių prognozė

Vidutinis 243.5 USD  31.03%

Aukščiausias 275 USD

Žemiausias 220 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ligand Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

7

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

102.5 / 109.24Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Weak Bullish Evidence

Rinkos nuotaikos

By Acuity

329 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat